Details of the Drug

General Information of Drug (ID: DMT5GNL)

Drug Name
Romidepsin
Synonyms
Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
Indication
Disease Entry ICD 11 Status REF
Cutaneous T-cell lymphoma 2B01 Approved [1]
Gastrin-producing neuroendocrine tumor N.A. Approved [2]
Glucagonoma N.A. Approved [2]
Insulinoma 2C10.1 Approved [2]
Lung carcinoid tumor N.A. Approved [2]
Melanoma 2C30 Approved [2]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified N.A. Approved [2]
Primary cutaneous T-cell lymphoma N.A. Approved [2]
Urethral cancer 2C93 Approved [2]
Peripheral T-cell lymphoma 2A90.C Phase 3 [3]
Renal cell carcinoma 2C90 Phase 3 [1]
⏷ Show the Full List of Indication(s)
ATC Code
L01XH02: Romidepsin
L01XH: Histone deacetylase (HDAC) inhibitors
L01X: OTHER ANTINEOPLASTIC AGENTS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 540.7
Logarithm of the Partition Coefficient (xlogp) 2.2
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Clearance
The clearance of drug is 8.4 L/h []
Half-life
The concentration or amount of drug in body reduced by one-half in 3 hours [5]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.64 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.07% [5]
Vd
The volume of distribution (Vd) of drug is 44.5 L []
Chemical Identifiers
Formula
C24H36N4O6S2
IUPAC Name
(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
Canonical SMILES
C/C=C\\1/C(=O)N[C@H](C(=O)O[C@H]\\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C
InChI
InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1
InChIKey
OHRURASPPZQGQM-GCCNXGTGSA-N
Cross-matching ID
PubChem CID
5352062
ChEBI ID
CHEBI:61080
CAS Number
128517-07-7
UNII
CX3T89XQBK
DrugBank ID
DB06176
TTD ID
D0L7LC
VARIDT ID
DR00233
INTEDE ID
DR1438
ACDINA ID
D01401
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone deacetylase 1 (HDAC1) TT6R7JZ HDAC1_HUMAN Inhibitor [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [8]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [9]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [10]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [11]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Gene/Protein Processing [12]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Gene/Protein Processing [13]
Bcl-2-interacting killer (BIK) OTTH1T3D BIK_HUMAN Gene/Protein Processing [14]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Gene/Protein Processing [15]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Gene/Protein Processing [16]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [17]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Protein Interaction/Cellular Processes [18]
Clusterin (CLU) OTQGG0JM CLUS_HUMAN Gene/Protein Processing [14]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Gene/Protein Processing [17]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Gene/Protein Processing [19]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Cutaneous T-cell lymphoma
ICD Disease Classification 2B01
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histone deacetylase 1 (HDAC1) DTT HDAC1 1.91E-11 0.44 1.3
P-glycoprotein 1 (ABCB1) DTP P-GP 5.54E-01 1.87E-01 4.30E-01
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 1.48E-59 -3.95E+00 -5.81E+00
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 2.38E-13 -2.40E+00 -1.69E+00
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 4.87E-05 -5.90E-01 -7.24E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.02E-14 -3.12E+00 -2.25E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC2 -7.7807 -5.5025 -8.3113 14.4052
EW-22 GDSC2 -9.8289 -8.3728 -9.8397 32.0163
EW-3 GDSC2 -9.5111 -7.3665 -9.6095 29.2724
EW-11 GDSC2 -9.461 -7.0568 -9.6161 29.0601
SaOS-2 GDSC2 -9.3871 -6.812 -9.5934 28.5845
NY GDSC2 -9.3729 -7.0509 -9.5216 28.1473
ES7 GDSC2 -9.1816 -6.8963 -9.3487 26.3305
SK-PN-DW GDSC2 -9.1607 -6.8197 -9.3446 26.2095
ES5 GDSC2 -9.0577 -7.4641 -9.1079 24.4792
ES8 GDSC2 -9.0005 -7.4389 -9.0503 23.903
HuO9 GDSC2 -8.9361 -7.448 -8.9805 23.229
EW-7 GDSC2 -8.8869 -7.0893 -8.9861 23.021
TC-71 GDSC2 -8.8802 -7.1731 -8.963 22.8684
NOS-1 [Human HNSCC] GDSC2 -8.8446 -7.2591 -8.9099 22.4197
HuO-3N1 GDSC2 -8.77 -5.8809 -9.2096 23.6918
A-673 GDSC2 -8.7423 -6.2693 -9.0462 22.6754
ES4 GDSC2 -8.7321 -6.6936 -8.9094 21.8859
EW-24 GDSC2 -8.6831 -6.3623 -8.9521 21.8935
HOS GDSC2 -8.6804 -6.3715 -8.9463 21.8498
EW-16 GDSC2 -8.6359 -6.4513 -8.8733 21.2489
CAL-72 GDSC2 -8.4921 -6.2572 -8.7783 20.0808
ES6 GDSC2 -8.3505 -5.7229 -8.8193 19.6959
CHSA8926 GDSC2 -8.3205 -6.1788 -8.6188 18.4343
EW-18 GDSC2 -8.2134 -6.4167 -8.4237 16.8729
MG-63 GDSC2 -8.0024 -5.595 -8.5027 16.423
SK-ES-1 GDSC2 -7.9152 -6.2748 -8.1472 14.0122
U2OS GDSC2 -7.8899 -4.947 -8.6688 16.9528
EW-1 GDSC2 -7.8654 -6.0741 -8.1666 13.9085
CAL-78 GDSC2 -7.7599 -5.401 -8.3341 14.4583
MHH-ES-1 GDSC2 -7.6732 -5.9238 -8.0216 12.2673
G-292 clone A141B1 GDSC2 -7.3914 -4.2623 -8.5034 14.1214
EW-13 GDSC2 -7.3249 -5.8129 -7.7074 9.017
H-EMC-SS GDSC2 -6.9895 -3.2332 -8.6451 13.6514
CADO-ES1 GDSC2 0.0466 7.1522 -9.0835 3.6731
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-220 GDSC2 -8.6719 -7.1149 -8.7486 20.7468
FLO-1 GDSC2 -8.4023 -6.1892 -8.7038 19.2685
SK-GT-4 GDSC2 -8.1928 -5.4807 -8.7498 18.6375
TE-12 GDSC2 -8.1195 -4.5479 -9.0811 20.249
OACP4 C GDSC2 -8.1112 -6.4463 -8.3032 15.7494
KYSE-50 GDSC2 -7.6338 11.6285 -16.6176 39.0851
KYAE-1 GDSC2 -7.6022 -6.109 -7.8723 11.106
ESO-51 GDSC2 -7.4386 2.2745 -11.7815 29.6661
ESO-26 GDSC2 -7.3102 -6.2182 -7.5193 7.8455
OACM5.1 C GDSC2 -7.0789 -4.7692 -7.9645 9.7177
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC2 -8.3478 -2.2145 -10.4005 27.8351
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SJNB-13 GDSC2 -9.2232 -6.8524 -9.4047 26.8212
NB69 GDSC2 -9.1509 -7.6799 -9.1818 25.3154
SJNB-14 GDSC2 -8.796 -7.0902 -8.8875 22.069
KP-N-YN GDSC2 -8.4357 -4.5373 -9.4066 23.3341
Kelly GDSC2 -8.3831 -5.7051 -8.861 20.0709
SK-N-DZ GDSC2 -8.1967 -6.5902 -8.3535 16.4118
TGW GDSC2 -7.9985 -6.7249 -8.1008 14.1299
SK-N-AS GDSC2 -7.9141 10.0127 -16.053 39.1365
CHP-134 GDSC2 -7.8521 -4.6613 -8.7614 17.355
CHP-212 GDSC2 -7.8311 -4.1522 -8.9784 18.5497
IMR-5 GDSC2 -7.7354 5.5463 -13.6709 35.1931
SK-N-BE(2)-M17 GDSC2 -7.0566 4.8054 -12.716 31.1364
NH-12 GDSC2 -7.0394 4.2046 -12.4011 30.2573
GOTO GDSC2 -7.0224 4.6836 -12.626 30.8076
SJNB-10 GDSC2 -6.9632 -4.9981 -7.746 7.9653
SJNB-7 GDSC2 -6.8955 3.751 -12.0525 28.838
SiMa GDSC2 -6.7806 6.2476 -13.2039 31.5528
GI-ME-N GDSC2 -6.6053 -1.2059 -9.3308 16.4835
NB(TU)1 GDSC2 -0.113 3.7386 -7.8799 0.4174
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 GDSC2 -8.0065 -5.9083 -8.3809 15.7349
Cancer Drug Sensitivity Data Curated from 42 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MDA-MB-330 GDSC2 -9.9795 -7.9669 -10.0263 33.7044
DU4475 GDSC2 -9.5774 -8.3702 -9.5826 29.4643
Hs 578T GDSC2 -9.5208 -6.7168 -9.764 30.0992
MDA-MB-453 GDSC2 -9.4348 -8.1831 -9.4432 28.0499
HCC1569 GDSC2 -8.9169 -7.7281 -8.9329 22.891
CAL-85-1 GDSC2 -8.8898 -7.0825 -8.9906 23.0592
MDA-MB-468 GDSC2 -8.6896 -6.1944 -9.0136 22.2596
MDA-MB-231 GDSC2 -8.6846 -7.2959 -8.7327 20.7251
HCC1954 GDSC2 -8.6407 -5.3839 -9.2612 23.4069
HCC1419 GDSC2 -8.6095 -6.7778 -8.754 20.4815
HCC2157 GDSC2 -8.3943 -7.1936 -8.437 17.7845
HCC1806 GDSC2 -8.2487 -5.5246 -8.7905 19.1034
EFM-19 GDSC2 -8.1109 -6.4205 -8.3111 15.7914
Evsa-T GDSC2 -8.0734 -6.2634 -8.3222 15.6876
JIMT-1 GDSC2 -7.9715 -6.1442 -8.2545 14.8629
OCUB-M GDSC2 -7.9616 -6.4803 -8.1297 14.1194
MDA-MB-157 GDSC2 -7.8957 -6.145 -8.1726 14.0715
EFM-192A GDSC2 -7.8533 -3.213 -9.4481 21.2823
HDQ-P1 GDSC2 -7.6021 -4.1849 -8.7412 16.3078
BT-474 GDSC2 -7.5315 -6.1332 -7.7877 10.3215
MFM-223 GDSC2 -7.4541 -5.9446 -7.7834 9.9788
T-47D GDSC2 -7.4295 4.9613 -13.1135 33.1589
CAMA-1 GDSC2 -7.4278 -5.047 -8.1626 12.1651
CAL-51 GDSC2 -7.414 -5.966 -7.7325 9.5179
AU565 GDSC2 -7.3961 0.1741 -10.6984 25.6393
MCF-7 GDSC2 -7.3047 7.2468 -14.1473 34.8799
HCC70 GDSC2 -7.2987 3.6446 -12.3435 30.8683
CAL-120 GDSC2 -7.2575 8.0972 -14.5318 35.4186
BT-549 GDSC2 -7.2159 -4.832 -8.0617 10.7892
HCC38 GDSC2 -7.1943 3.562 -12.2124 30.1898
HCC1143 GDSC2 -7.1328 -3.6957 -8.5429 13.4886
HCC1428 GDSC2 -7.1024 -6.2669 -7.2808 5.6009
HCC1500 GDSC2 -7.046 6.1217 -13.3648 32.6338
BT-20 GDSC2 -6.788 -5.2938 -7.4424 5.4912
MDA-MB-436 GDSC2 -6.7752 8.0562 -14.1036 33.4282
COLO 824 GDSC2 -6.7224 -3.5937 -8.2348 10.2899
HCC1937 GDSC2 -6.6717 -4.6414 -7.6684 6.568
MDA-MB-415 GDSC2 -6.623 -0.7901 -9.5533 17.7483
HCC1187 GDSC2 -6.4958 -2.8538 -8.417 10.7663
MDA-MB-361 GDSC2 -0.8504 18.5355 -14.7936 23.2699
ZR-75-30 GDSC2 -0.4349 8.7878 -10.0061 7.7609
MRK-nu-1 GDSC2 0.0074 3.0336 -7.604 0.11
⏷ Show the Full List of 42 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
D283 Med GDSC2 -9.5646 -8.4521 -9.5678 29.3259
A-172 GDSC2 -9.4875 -8.4252 -9.4902 28.5501
42-MG-BA GDSC2 -9.4622 -8.2444 -9.469 28.3168
H4 GDSC2 -9.4077 -7.1819 -9.532 28.3699
KS-1 [Human Krukenberg tumour] GDSC2 -9.369 -6.0781 -9.7896 29.4862
U-251MG GDSC2 -9.1004 -7.3982 -9.1628 24.9708
GI-1 GDSC2 -8.9428 -7.7009 -8.9619 23.1667
CAS-1 GDSC2 -8.9046 -5.8428 -9.3683 25.1505
SF268 GDSC2 -8.8963 -7.2417 -8.9683 22.9732
8-MG-BA GDSC2 -8.8538 -6.6748 -9.0472 23.1908
D-263MG GDSC2 -8.8382 -6.8996 -8.9739 22.7259
YH-13 GDSC2 -8.7417 -5.6971 -9.2471 23.7703
PFSK-1 GDSC2 -8.6766 -6.802 -8.8212 21.1544
GaMG GDSC2 -8.6729 -7.2625 -8.7252 20.6294
ONS-76 GDSC2 -8.567 -6.1619 -8.8916 21.0411
SW1088 GDSC2 -8.5291 -5.7757 -8.9897 21.421
D-392MG GDSC2 -8.4931 -5.7391 -8.9652 21.1289
T98G GDSC2 -8.3909 -6.7044 -8.5342 18.2842
Becker GDSC2 -8.2523 -6.1699 -8.5482 17.7393
SF539 GDSC2 -8.1617 -5.585 -8.6743 18.0735
AM-38 GDSC2 -8.1134 -5.7079 -8.5736 17.2919
SK-MG-1 GDSC2 -8.0719 -6.3061 -8.3061 15.5907
Daoy GDSC2 -7.9721 -5.904 -8.3459 15.3887
U-118MG GDSC2 -7.9129 -5.7606 -8.3406 15.1123
M059J GDSC2 -7.8366 -5.6291 -8.3152 14.6522
DK-MG GDSC2 -7.8144 -4.7896 -8.6647 16.6387
KINGS-1 GDSC2 -7.6587 -4.1586 -8.8081 16.912
LN-405 GDSC2 -7.4226 -3.2714 -9.0162 17.3032
KALS-1 GDSC2 -7.3203 -4.9958 -8.0823 11.2842
U-87MG ATCC GDSC2 -7.1253 -5.2724 -7.7629 8.6214
LN-229 GDSC2 -7.0685 -4.3162 -8.1781 11.0169
LN-18 GDSC2 -6.8551 -5.9552 -7.1769 4.0441
DBTRG-05MG GDSC2 -6.575 -4.0215 -7.8981 7.741
GB-1 GDSC2 -5.3323 1.5382 -9.7 15.0138
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TGBC24TKB GDSC2 -7.5137 4.2536 -12.8334 32.7619
ETK-1 GDSC2 -7.4733 -5.0106 -8.2243 12.708
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RL95-2 GDSC2 -8.8381 -6.4122 -9.1056 23.4332
ESS-1 GDSC2 -8.6145 -7.1317 -8.6836 20.1311
MFE-319 GDSC2 -7.4535 -5.8285 -7.8325 10.2673
AN3-CA GDSC2 -7.3695 -4.5983 -8.3202 12.9222
MFE-280 GDSC2 -7.2622 -5.1378 -7.9586 10.3151
MFE-296 GDSC2 -7.0869 -5.5685 -7.5841 7.3798
KLE GDSC2 -6.9385 -4.3465 -8.0465 9.7731
EN GDSC2 -6.6754 -4.2286 -7.8779 7.904
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 128 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Karpas-299 GDSC2 -10.6601 -9.3769 -10.6613 40.3097
JVM-2 GDSC2 -10.2209 -8.6072 -10.232 35.9507
L-1236 GDSC2 -10.0271 -7.9372 -10.0798 34.2099
AMO1 GDSC2 -9.8531 -7.3759 -9.9769 32.8152
DEL GDSC2 -9.7591 -8.6569 -9.7611 31.2715
Loucy GDSC2 -9.747 -7.1712 -9.9024 31.9121
SU-DHL-5 GDSC2 -9.7338 -8.6575 -9.7356 31.0169
WSU-NHL GDSC2 -9.7009 -7.454 -9.7989 31.1691
LC4-1 GDSC2 -9.6761 -8.2689 -9.6872 30.4847
RPMI-6666 GDSC2 -9.6394 -8.2825 -9.649 30.1089
BC-1 GDSC2 -9.616 -8.4119 -9.6208 29.85
DND-41 GDSC2 -9.5867 -8.3945 -9.5915 29.5558
H9 GDSC2 -9.5559 -8.414 -9.5597 29.2421
Jiyoye GDSC2 -9.5531 -4.1706 -10.7195 34.395
ST486 GDSC2 -9.5199 -8.2853 -9.5266 28.8952
SUP-B15 GDSC2 -9.4344 -8.2539 -9.4404 28.0334
MLMA GDSC2 -9.4298 -8.3415 -9.4334 27.9752
JURL-MK1 GDSC2 -9.3945 -7.7645 -9.43 27.7825
SU-DHL-10 GDSC2 -9.3208 -8.4725 -9.3215 26.8671
CCRF-CEM GDSC2 -9.3046 -8.2977 -9.3073 26.7145
L-540 GDSC2 -9.2766 -8.239 -9.2802 26.4376
EoL-1 GDSC2 -9.2733 -8.3592 -9.2748 26.3943
VL51 GDSC2 -9.2093 -8.305 -9.211 25.7531
MOLT-16 GDSC2 -9.1885 -8.3035 -9.19 25.5434
JVM-3 GDSC2 -9.1858 -7.4851 -9.2417 25.7938
697 GDSC2 -9.1812 -8.2579 -9.1832 25.4724
MHH-CALL-2 GDSC2 -9.1785 -8.0558 -9.1856 25.4715
KMS-12-BM GDSC2 -9.1502 -7.9251 -9.1625 25.2138
ALL-SIL GDSC2 -9.139 -7.5903 -9.1787 25.241
LAMA-84 GDSC2 -9.1118 -6.9854 -9.2522 25.4919
BE-13 GDSC2 -9.1068 -8.1408 -9.11 24.7316
Karpas-1106P GDSC2 -9.0889 -8.2783 -9.0899 24.5416
SU-DHL-6 GDSC2 -9.0732 -8.1409 -9.076 24.3929
Kasumi-1 GDSC2 -9.0689 -8.1076 -9.0723 24.3527
MOLM-13 GDSC2 -9.043 -7.9497 -9.051 24.1161
EB2 GDSC2 -9.0303 -7.6129 -9.0615 24.1066
U266B1 GDSC2 -9.0096 -7.6773 -9.0336 23.8618
NALM-6 GDSC2 -8.9953 -8.0175 -8.9998 23.6194
U-698-M GDSC2 -8.99 -7.7909 -9.0047 23.6179
KY821 GDSC2 -8.959 -8.1629 -8.9602 23.2387
DoHH2 GDSC2 -8.9231 -8.2717 -8.9234 22.874
Farage GDSC2 -8.8653 -7.9704 -8.8688 22.31
Hs 445 GDSC2 -8.8509 -7.3513 -8.9027 22.4128
IM-9 GDSC2 -8.8506 -6.781 -9.0161 23.0089
SUP-HD1 GDSC2 -8.8374 -6.79 -8.9994 22.8582
Daudi GDSC2 -8.8313 -7.963 -8.8344 21.9666
CESS GDSC2 -8.8172 -7.6798 -8.8325 21.8867
SUP-T1 GDSC2 -8.8076 -7.6439 -8.8251 21.8019
MOLT-13 GDSC2 -8.7877 -7.5359 -8.8135 21.6444
CTV-1 GDSC2 -8.7853 -6.3021 -9.0825 23.0673
KOPN-8 GDSC2 -8.7712 -7.095 -8.8597 21.8048
JSC-1 GDSC2 -8.7086 -7.2212 -8.7698 21.0339
A4/Fukuda GDSC2 -8.684 -7.2525 -8.7386 20.7528
Namalwa GDSC2 -8.6492 -7.3239 -8.6911 20.3378
BL-41 GDSC2 -8.6368 -7.8353 -8.6398 20.0144
PF-382 GDSC2 -8.6318 -7.0569 -8.7162 20.3852
A3/Kawakami GDSC2 -8.6161 -7.8869 -8.6178 19.8004
Reh GDSC2 -8.5477 -6.6433 -8.7218 20.0217
P30/OHK GDSC2 -8.5472 -6.65 -8.7193 20.0059
MEG-01 GDSC2 -8.5308 -6.9511 -8.6281 19.4406
OPM-2 GDSC2 -8.4914 -6.6036 -8.6712 19.4889
HL-60 GDSC2 -8.4873 -6.3627 -8.7389 19.8413
Ramos.2G6.4C10 GDSC2 -8.4864 -7.3677 -8.513 18.6257
CML-T1 GDSC2 -8.4577 -7.189 -8.5056 18.4476
SCC-3 GDSC2 -8.4101 -7.1051 -8.4679 18.0217
P32/ISH GDSC2 -8.409 -6.7693 -8.5374 18.3851
RPMI-8226 GDSC2 -8.4029 -6.726 -8.5417 18.3801
SR GDSC2 -8.3849 -6.8371 -8.4949 18.045
SKM-1 GDSC2 -8.3574 -6.7286 -8.4914 17.8984
HDLM-2 GDSC2 -8.3482 -6.0602 -8.6905 18.9572
L-363 GDSC2 -8.3135 -6.3619 -8.5501 18.0203
BALL-1 GDSC2 -8.2734 -6.6172 -8.4295 17.1763
ML-2 GDSC2 -8.2079 -6.6215 -8.3569 16.4818
HC-1 GDSC2 -8.1907 -6.2461 -8.4552 16.9485
MHH-PREB-1 GDSC2 -8.1658 -6.1972 -8.4452 16.7829
ARH-77 GDSC2 -8.1642 -6.666 -8.297 15.9556
GA-10 GDSC2 -8.1043 -6.1295 -8.4028 16.2765
Ku812 GDSC2 -8.1032 -6.4897 -8.2811 15.5913
ALL-PO GDSC2 -8.0979 -6.0863 -8.4115 16.2981
OCI-AML-3 GDSC2 -8.0507 -6.6241 -8.1847 14.8248
Karpas-422 GDSC2 -8.0106 -6.3374 -8.2291 14.8902
DB GDSC2 -8.0063 14.7156 -18.4792 41.4958
Raji GDSC2 -7.997 -6.6454 -8.1201 14.2276
MN-60 GDSC2 -7.9911 -4.4044 -9.0183 19.3879
NCI-H929 GDSC2 -7.9339 -6.0523 -8.2482 14.6663
GR-ST GDSC2 -7.8367 -4.8504 -8.6591 16.6904
KCL-22 GDSC2 -7.8254 -6.5683 -7.9547 12.5425
RC-K8 GDSC2 -7.8164 -5.4028 -8.3913 15.0205
ATN-1 GDSC2 -7.8132 -6.5582 -7.9444 12.4302
K-562 GDSC2 -7.7885 -6.2835 -8.0072 12.671
MM1.S GDSC2 -7.7336 -5.6312 -8.2072 13.6021
CA46 GDSC2 -7.7287 -4.9386 -8.5107 15.3936
Karpas-620 GDSC2 -7.7151 -5.768 -8.1299 13.0724
Karpas-45 GDSC2 -7.6684 -6.4006 -7.8367 11.187
SU-DHL-8 GDSC2 -7.6609 6.4839 -14.0735 35.7149
L-428 GDSC2 -7.6582 -6.3441 -7.8452 11.1903
TK [Human B-cell lymphoma] GDSC2 -7.623 -6.3935 -7.79 10.7262
Jurkat GDSC2 -7.6063 -6.3841 -7.7751 10.5695
WIL2 NS GDSC2 -7.5269 -6.5069 -7.6482 9.5097
P12-Ichikawa GDSC2 -7.4645 -6.5885 -7.5552 8.7163
GDM-1 GDSC2 -7.4641 -6.1426 -7.7125 9.6056
KE-37 GDSC2 -7.4593 -6.3681 -7.6219 9.0655
OCI-AML-2 GDSC2 -7.3936 -6.6264 -7.4669 7.9104
KMOE-2 GDSC2 -7.3909 -6.3897 -7.5403 8.3077
Karpas-231 GDSC2 -7.387 -6.3399 -7.5543 8.3698
EM-2 GDSC2 -7.3613 -6.5081 -7.4677 7.77
KM-H2 GDSC2 -7.3501 3.9925 -12.5615 31.6
HH [Human lymphoma] GDSC2 -7.3309 -1.318 -9.899 21.7879
SK-MM-2 GDSC2 -7.3156 -3.3218 -8.8933 16.214
OCI-M1 GDSC2 -7.2835 -6.6423 -7.3424 6.7291
TUR GDSC2 -7.2732 -6.4519 -7.3913 6.955
MOLP-8 GDSC2 -7.26 -6.1185 -7.5077 7.573
HEL GDSC2 -7.2088 -6.5466 -7.2894 6.1007
DG-75 GDSC2 -7.2066 2.552 -11.7188 28.7396
SUP-M2 GDSC2 -7.2009 -6.4788 -7.3037 6.1464
MOLT-4 GDSC2 -7.1732 -6.1558 -7.4016 6.5979
OCI-AML-5 GDSC2 -7.1721 -6.3745 -7.3112 6.0654
LP-1 GDSC2 -7.1265 -4.2977 -8.24 11.5946
RPMI-8866 GDSC2 -7.0737 -5.3377 -7.6824 7.9419
NOMO-1 GDSC2 -7.0709 -6.0972 -7.3222 5.7228
EJM GDSC2 -7.064 -6.1422 -7.295 5.533
Granta-519 GDSC2 -7.0617 -5.2417 -7.7177 8.1202
JJN-3 GDSC2 -7.0264 -6.0719 -7.2888 5.3511
KG-1 GDSC2 -6.8211 -4.6041 -7.8149 7.9458
VAL GDSC2 -6.7562 -3.4079 -8.3564 11.1503
ME1 GDSC2 -6.7207 5.714 -12.8869 30.6292
RS4;11 GDSC2 -0.3308 18.8101 -14.5718 21.9889
HAL-01 GDSC2 0.1153 3.3932 -7.6859 0.1602
⏷ Show the Full List of 128 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW13 GDSC2 -8.7639 -6.998 -8.8713 21.8313
BFTC-909 GDSC2 -8.5749 -4.0845 -9.7504 25.7144
CAL-54 GDSC2 -8.5501 -6.6558 -8.7209 20.028
RXF 393L GDSC2 -8.4019 -5.9559 -8.7862 19.7289
KTCTL-195 GDSC2 -8.1947 12.4033 -17.4888 41.15
A-498 GDSC2 -7.7968 -5.0998 -8.5059 15.6252
SN12C GDSC2 -7.7091 -5.7825 -8.1176 12.9756
VMRC-RCZ GDSC2 -7.5496 -5.6256 -8.0199 11.7617
TK-10 GDSC2 -7.3568 -4.1271 -8.5366 14.2045
HA7-RCC GDSC2 -7.2942 -5.6744 -7.7388 9.0887
KMRC-20 GDSC2 -7.2912 -5.1029 -8.0033 10.6936
786-O GDSC2 -7.1924 -5.1431 -7.8891 9.6384
LB996-RCC GDSC2 -7.1834 -4.219 -8.3308 12.3476
ACHN GDSC2 -7.1682 -5.68 -7.6108 7.8389
OS-RC-2 GDSC2 -6.7113 -4.8365 -7.6044 6.2805
A-704 GDSC2 -6.6789 -3.9965 -7.9968 8.6652
769-P GDSC2 -6.2455 -2.9928 -8.149 8.419
RCC10RGB GDSC2 -0.6983 8.9204 -10.2077 8.9083
NCC010 GDSC2 -0.1938 5.3798 -8.4999 1.8878
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 46 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KM12 GDSC2 -9.2428 -6.559 -9.5038 27.431
SNU-175 GDSC2 -9.182 -6.8089 -9.3705 26.4466
SW626 GDSC2 -9.1748 -7.1183 -9.2923 26.0031
RCM-1 [Human ESC] GDSC2 -9.1417 -6.6546 -9.3669 26.2368
CaR-1 GDSC2 -9.0067 -6.5966 -9.2355 24.9083
HT-29 GDSC2 -8.9871 -7.3192 -9.0534 23.8545
MDST8 GDSC2 -8.9563 -6.5005 -9.2081 24.5281
DiFi GDSC2 -8.9283 -7.5517 -8.9602 23.0865
SW48 GDSC2 -8.8219 -6.0616 -9.2019 23.8816
HCC2998 GDSC2 -8.744 -6.7657 -8.9037 21.9101
RKO GDSC2 -8.5716 -3.8156 -9.8688 26.291
C2BBe1 GDSC2 -8.3314 11.7698 -17.2922 41.2992
SW620 GDSC2 -8.216 -6.4226 -8.4247 16.8905
GP5d GDSC2 -8.1516 -5.6995 -8.6173 17.7035
SNU-C1 GDSC2 -8.119 -5.2821 -8.7562 18.3728
HT-55 GDSC2 -8.063 -6.2613 -8.3117 15.5831
SNU-C5 GDSC2 -8.0415 -5.6262 -8.531 16.7482
LS411N GDSC2 -7.8878 -6.278 -8.1164 13.7188
SNU-C2B GDSC2 -7.7925 -3.5694 -9.2187 19.7852
LoVo GDSC2 -7.7744 -5.613 -8.2573 14.0611
COLO205 GDSC2 -7.5708 -5.8552 -7.9427 11.388
HCT 116 GDSC2 -7.5647 -6.4178 -7.7185 10.0693
LS123 GDSC2 -7.4914 4.5882 -12.981 33.04
SW837 GDSC2 -7.4806 2.211 -11.7866 29.8155
NCI-H747 GDSC2 -7.2392 -5.7807 -7.6351 8.2529
SK-CO-1 GDSC2 -7.1332 -5.7788 -7.5302 7.218
SNU-61 GDSC2 -7.046 -5.787 -7.4407 6.3509
SW948 GDSC2 -6.9046 -4.4571 -7.9614 9.1305
SW1417 GDSC2 -6.8268 -2.5324 -8.854 14.4036
LS513 GDSC2 -6.7408 -4.3185 -7.8883 8.1639
HT115 GDSC2 -6.7391 3.7893 -11.94 28.0405
LS180 GDSC2 -6.6541 -4.8364 -7.5561 5.8058
SNU-1040 GDSC2 -6.6234 -4.2156 -7.8409 7.5187
SNU-81 GDSC2 -6.517 0.7698 -10.2455 20.887
CCK-81 GDSC2 -6.4706 7.0428 -13.3434 31.0589
NCI-H716 GDSC2 -6.4569 -2.5684 -8.5279 11.3392
T84 GDSC2 -6.4371 -2.0939 -8.7489 12.6242
SW1116 GDSC2 -6.3102 0.4518 -9.9176 18.7091
COLO 678 GDSC2 -5.8578 5.1051 -11.8768 25.4248
HCT 15 GDSC2 -5.7001 1.587 -10.0016 17.451
SNU-407 GDSC2 -0.8753 6.4792 -9.25 5.2117
SW1463 GDSC2 -0.4772 9.3183 -10.2606 8.8259
LS1034 GDSC2 -0.3758 4.5041 -8.2484 1.2726
COLO 320HSR GDSC2 -0.1706 2.7972 -7.5857 0.1118
CW-2 GDSC2 0.0536 7.5025 -9.221 4.1698
CL-11 GDSC2 0.4256 3.3904 -7.5827 0.0716
⏷ Show the Full List of 46 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC2 -6.725 -3.7562 -8.1559 9.803
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-398 GDSC2 -8.7032 -4.8135 -9.5625 25.2925
JHH-1 GDSC2 -8.6052 -6.7987 -8.7441 20.4081
JHH-6 GDSC2 -8.239 -5.8751 -8.6418 18.212
SNU-387 GDSC2 -8.1971 -4.6859 -9.0975 20.65
SK-HEP-1 GDSC2 -8.0207 -5.4415 -8.5862 16.9846
SNU-423 GDSC2 -7.9241 13.5657 -17.8344 40.8384
JHH-2 GDSC2 -7.6795 -4.6034 -8.6177 15.8508
Hep 3B2.1-7 GDSC2 -7.5001 -6.1358 -7.7534 9.9925
HLE GDSC2 -7.0748 4.7811 -12.7193 31.197
Hep-G2/C3A GDSC2 -6.9418 -5.3004 -7.5776 6.8391
HuH-1 GDSC2 -6.589 5.9088 -12.8745 30.2418
JHH-7 GDSC2 -1.0557 15.5354 -13.4932 20.4654
JHH-4 GDSC2 -0.5104 13.7593 -12.2995 16.163
Huh-7 GDSC2 -0.3043 7.9555 -9.5824 5.9192
SNU-449 GDSC2 0.3096 3.1162 -7.532 0.0553
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 129 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H250 GDSC2 -10.1182 -8.534 -10.1297 34.9223
NCI-H209 GDSC2 -10.0767 -6.7 -10.375 35.7996
A-549 GDSC2 -9.885 -7.2566 -10.0345 33.2554
NCI-H2795 GDSC2 -9.8779 -7.0317 -10.0754 33.4111
LXF 289 GDSC2 -9.8495 -7.432 -9.9629 32.7294
NCI-H1651 GDSC2 -9.824 -7.8567 -9.8739 32.162
NCI-H2810 GDSC2 -9.6014 -6.2982 -9.9721 31.5115
NCI-H1755 GDSC2 -9.4683 -6.9556 -9.6471 29.2537
NCI-H2227 GDSC2 -9.4674 -6.9784 -9.6408 29.2174
NCI-H2461 GDSC2 -9.4671 -7.1833 -9.5962 28.9885
NCI-H2122 GDSC2 -9.3425 -6.5962 -9.6021 28.4141
Ms-1 GDSC2 -9.3224 -8.1781 -9.3284 26.9097
DMS 79 GDSC2 -9.306 -8.0637 -9.3161 26.7658
NCI-H1915 GDSC2 -9.2777 -7.5374 -9.3327 26.7113
HCC78 GDSC2 -9.2207 -7.008 -9.3656 26.6053
NCI-H322M GDSC2 -9.202 -5.6639 -9.7534 28.5121
NCI-H2373 GDSC2 -9.1322 -7.2328 -9.2243 25.4441
LOU-NH91 GDSC2 -9.0942 -8.1291 -9.0975 24.6058
NCI-H810 GDSC2 -9.0932 -7.3634 -9.1604 24.9227
LCLC-103H GDSC2 -9.0388 -8.3324 -9.0391 24.035
NCI-H446 GDSC2 -9.0342 -7.9969 -9.0401 24.017
NCI-H524 GDSC2 -8.9971 -8.1778 -8.9984 23.6214
NCI-H2023 GDSC2 -8.9353 -6.6493 -9.1431 24.0829
DMS 273 GDSC2 -8.9092 -6.6489 -9.1147 23.8098
NCI-H211 GDSC2 -8.9052 -7.9226 -8.9108 22.7209
NCI-H1975 GDSC2 -8.9034 -7.2609 -8.9729 23.0313
CPC-N GDSC2 -8.8832 -7.1978 -8.9618 22.8764
EMC-BAC-2 GDSC2 -8.8793 -6.9533 -9.0064 23.0925
Lu-139 GDSC2 -8.8488 -7.0061 -8.9618 22.7119
EBC-1 GDSC2 -8.8417 -6.6571 -9.0388 23.0893
NCI-H1666 GDSC2 -8.8355 -6.1812 -9.1763 23.804
LCLC-97TM1 GDSC2 -8.7908 -6.7684 -8.9541 22.3987
SBC-5 GDSC2 -8.7517 -7.5627 -8.7732 21.2615
NCI-H1993 GDSC2 -8.7503 -6.6306 -8.9463 22.1692
NCI-H526 GDSC2 -8.6598 -6.7435 -8.8176 21.0567
HCC44 GDSC2 -8.6555 -6.4602 -8.892 21.4404
NCI-H1963 GDSC2 -8.6486 -7.0311 -8.7394 20.5873
HCC827 GDSC2 -8.6229 -5.3208 -9.2679 23.3665
NCI-H2804 GDSC2 -8.6128 -6.2223 -8.9209 21.4065
SW1271 GDSC2 -8.5287 -6.4135 -8.768 20.1877
NCI-H2731 GDSC2 -8.5146 -6.8312 -8.6376 19.4147
NCI-H3122 GDSC2 -8.4986 -4.9129 -9.3077 23.057
NCI-H1869 GDSC2 -8.47 -4.5361 -9.4422 23.6682
NCI-H650 GDSC2 -8.4453 -5.97 -8.8277 20.1506
EPLC-272H GDSC2 -8.366 -4.9097 -9.1719 21.7546
Calu-6 GDSC2 -8.3658 -5.9865 -8.7362 19.2914
NCI-H2818 GDSC2 -8.3478 -4.8373 -9.1847 21.751
PC-14 GDSC2 -8.3455 -6.5474 -8.5281 18.0432
HARA [Human squamous cell lung carcinoma] GDSC2 -8.3258 -6.0248 -8.6791 18.7962
HCC366 GDSC2 -8.2415 -5.9001 -8.635 18.1841
SK-MES-1 GDSC2 -8.2182 -5.4828 -8.7755 18.8905
NCI-H358 GDSC2 -8.2008 -6.5314 -8.375 16.5484
VMRC-LCD GDSC2 -8.1925 -6.6516 -8.3318 16.2741
LK-2 GDSC2 -8.1705 -6.4386 -8.3702 16.3849
HOP-92 GDSC2 -8.1674 -5.5104 -8.7108 18.3079
DMS 114 GDSC2 -8.1483 -4.5052 -9.1295 20.6373
COR-L311 GDSC2 -8.0971 -6.5195 -8.2654 15.4771
NCI-H1435 GDSC2 -8.0924 -5.7363 -8.54 17.0113
NCI-H2170 GDSC2 -8.092 -6.2272 -8.3548 15.9522
NCI-H1568 GDSC2 -8.0895 -0.5097 -10.9857 29.1913
NCI-H520 GDSC2 -8.0775 -3.6143 -9.4727 22.2628
UMC-11 GDSC2 -8.0712 -5.9732 -8.425 16.2608
NCI-H1944 GDSC2 -8.0598 -6.1447 -8.3493 15.7814
LC-1/sq GDSC2 -8.0436 -6.1025 -8.3472 15.7
NCI-H441 GDSC2 -7.9989 6.3014 -14.2777 37
SHP-77 GDSC2 -7.9552 -5.8406 -8.3531 15.3596
NCI-H1581 GDSC2 -7.9342 -6.1885 -8.1982 14.3826
NCI-H2029 GDSC2 -7.9312 -5.508 -8.4649 15.9131
Lu-165 GDSC2 -7.9177 7.9634 -15.0345 37.8932
COR-L23 GDSC2 -7.9051 9.3958 -15.7376 38.7534
NCI-H2722 GDSC2 -7.8836 -5.8672 -8.2667 14.5618
COR-L105 GDSC2 -7.8785 0.62 -11.3498 29.7278
NCI-H2228 GDSC2 -7.8519 -3.5062 -9.3059 20.4943
NCI-H596 GDSC2 -7.8278 -5.0559 -8.5569 16.0487
NCI-H1792 GDSC2 -7.7977 -5.6826 -8.2521 14.1246
NCI-H3255 GDSC2 -7.7832 -4.3744 -8.8269 17.4822
NCI-H196 GDSC2 -7.768 -6.1653 -8.0281 12.7016
NCI-H1155 GDSC2 -7.7665 -6.3406 -7.9635 12.3288
NCI-H2087 GDSC2 -7.7369 -5.0998 -8.4454 15.0337
NCI-H82 GDSC2 -7.7288 -6.6887 -7.8159 11.3447
NCI-H1876 GDSC2 -7.7067 -6.0888 -7.9915 12.232
NCI-H1623 GDSC2 -7.6432 -6.1843 -7.8872 11.3648
SK-LU-1 GDSC2 -7.6359 -5.3482 -8.2312 13.3616
Lu-135 GDSC2 -7.5927 -6.1388 -7.8506 10.9411
NCI-H2595 GDSC2 -7.5911 -4.8061 -8.4358 14.4269
NCI-H2369 GDSC2 -7.5564 3.1133 -12.3024 31.5481
RERF-LC-KJ GDSC2 -7.5295 -5.99 -7.8434 10.6374
Lu-99A GDSC2 -7.529 9.9103 -15.6697 37.7482
NCI-H1092 GDSC2 -7.5228 -5.7219 -7.9502 11.241
NCI-H1355 GDSC2 -7.5223 -3.6756 -8.9114 17.0351
NCI-H1694 GDSC2 -7.4546 -6.4423 -7.5909 8.87
COLO 668 GDSC2 -7.4404 -5.4963 -7.9668 11.0216
Lu-65 GDSC2 -7.4274 -4.7903 -8.2837 12.9047
Calu-3 GDSC2 -7.4124 -3.5185 -8.8856 16.4995
IST-SL2 GDSC2 -7.3411 -6.207 -7.5566 8.1902
NCI-H1299 GDSC2 -7.2217 -4.1317 -8.4089 12.9595
KNS-62 GDSC2 -7.2072 -4.3459 -8.2905 12.178
SBC-3 GDSC2 -7.199 -6.2272 -7.3985 6.6835
NCI-H2869 GDSC2 -7.1422 -2.0913 -9.3477 18.2529
NCI-H345 GDSC2 -7.1391 -6.494 -7.2316 5.4702
NCI-H2085 GDSC2 -7.0822 2.868 -11.7698 28.5205
SW1573 GDSC2 -7.0352 -3.5263 -8.5397 13.1518
NCI-H841 GDSC2 -6.9949 -5.3839 -7.5859 7.0701
EKVX GDSC2 -6.9344 -0.1782 -10.1219 21.5811
NCI-H661 GDSC2 -6.9053 -4.0213 -8.179 10.4992
HOP-62 GDSC2 -6.8998 -4.1066 -8.1316 10.185
NCI-H1563 GDSC2 -6.8989 -4.1902 -8.0892 9.9161
NCI-H2141 GDSC2 -6.7972 -3.9211 -8.1351 9.8897
NCI-H1693 GDSC2 -6.7857 -3.308 -8.4314 11.7047
NCI-H522 GDSC2 -6.7699 -3.8008 -8.1718 10.0376
NCI-H23 GDSC2 -6.7682 3.7216 -11.9306 28.0954
IA-LM GDSC2 -6.7466 1.7178 -10.9106 24.4365
RERF-LC-Sq1 GDSC2 -6.6827 -2.3201 -8.8382 13.8728
NCI-H1781 GDSC2 -6.6639 3.1249 -11.545 26.5332
NCI-H2135 GDSC2 -6.6043 -3.6123 -8.1268 9.2664
NCI-H1048 GDSC2 -6.5378 5.8679 -12.8116 29.9443
NCI-H720 GDSC2 -6.5311 0.362 -10.0533 20.0184
NCI-H2803 GDSC2 -6.4239 -3.6985 -7.9375 7.5698
ABC-1 GDSC2 -6.3878 4.1019 -11.8048 26.6156
NCI-H2405 GDSC2 -6.3652 -2.2816 -8.5973 11.5063
A-427 GDSC2 -6.1285 4.1415 -11.6133 25.2623
NCI-H2591 GDSC2 -5.7708 0.5153 -9.5245 15.2101
NCI-H727 GDSC2 -5.7561 4.4271 -11.458 23.7256
NCI-H226 GDSC2 -4.8566 4.0959 -10.6069 18.1257
DMS 53 GDSC2 -4.3706 6.7133 -11.5356 20.6692
NCI-H513 GDSC2 -0.7495 12.5719 -11.8965 15.2257
HCC15 GDSC2 -0.5637 20.3303 -15.4616 24.2337
NCI-H1793 GDSC2 0.1381 10.3175 -10.3622 8.4398
NCI-H1650 GDSC2 0.4594 4.0523 -7.7879 0.2112
⏷ Show the Full List of 129 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC2 -8.7003 -6.9035 -8.8229 21.2742
Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OE33 GDSC2 -9.5136 -7.6557 -9.5685 29.0762
EC-GI-10 GDSC2 -9.3118 -7.7586 -9.3436 26.9341
KYSE-510 GDSC2 -9.0557 -6.211 -9.4058 26.0402
OE19 GDSC2 -8.9449 -8.013 -8.9486 23.1094
TE-8 GDSC2 -8.9022 -6.8461 -9.0563 23.4655
TE-1 GDSC2 -8.786 -6.4149 -9.0479 22.8827
KYSE-270 GDSC2 -8.7696 -6.1699 -9.1086 23.1386
TE-15 GDSC2 -8.5294 -6.4005 -8.7729 20.2176
COLO 680N GDSC2 -8.2281 -6.2628 -8.4901 17.3078
KYSE-180 GDSC2 -8.1586 -6.3837 -8.3746 16.3565
OE21 GDSC2 -8.0071 -5.9509 -8.3651 15.6466
TE-4 GDSC2 -7.9537 -6.4896 -8.1182 14.0204
KYSE-450 GDSC2 -7.7347 -5.4835 -8.2721 13.9907
KYSE-70 GDSC2 -7.6301 -4.7373 -8.5064 14.9979
KYSE-410 GDSC2 -7.6045 -4.9198 -8.3959 14.235
TE-9 GDSC2 -7.5369 -5.3965 -8.1093 12.2492
KYSE-140 GDSC2 -7.4454 -5.1575 -8.1281 12.0191
TE-5 GDSC2 -6.9714 -4.4985 -8.0004 9.5887
KYSE-520 GDSC2 -0.9603 14.1677 -12.7797 18.3243
TE-6 GDSC2 -0.3847 16.1017 -13.319 18.9531
⏷ Show the Full List of 20 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DOV13 GDSC2 -9.1964 -7.2118 -9.2976 26.1347
OVCAR-5 GDSC2 -9.0279 -5.9201 -9.4739 26.271
TOV-21G GDSC2 -8.7017 -5.2147 -9.3941 24.3918
OVCAR-8 GDSC2 -8.5546 -6.6363 -8.7312 20.1048
EFO-27 GDSC2 -8.3955 -5.7172 -8.8694 20.1712
TOV-112D GDSC2 -8.2438 -6.0146 -8.5947 17.9654
SK-OV-3 GDSC2 -8.1626 -5.9517 -8.531 17.2549
A2780 GDSC2 -8.1571 -6.1197 -8.4632 16.8466
OVK18 GDSC2 -7.8145 -5.9993 -8.1411 13.5473
TYK-nu GDSC2 -7.6473 -5.1655 -8.3253 13.9708
OVTOKO GDSC2 -7.6182 5.5139 -13.5527 34.6274
ES-2 GDSC2 -7.5915 -5.1244 -8.2883 13.5365
IGROV-1 GDSC2 -7.3705 -0.3643 -10.408 24.3148
OV-90 GDSC2 -7.32 -5.0973 -8.0338 10.9844
Kuramochi GDSC2 -7.1977 -3.4181 -8.7387 14.8941
OVCAR-3 GDSC2 -7.1352 -6.0097 -7.4267 6.5986
OVISE GDSC2 -6.9146 -6.0859 -7.1714 4.2206
OV56 GDSC2 -6.511 -3.5709 -8.0711 8.6505
OAW28 GDSC2 -6.1715 2.1009 -10.6291 21.6009
OVCAR-4 GDSC2 -6.1069 -1.4711 -8.7975 12.0072
EFO-21 GDSC2 -0.7387 11.7693 -11.5184 13.9175
OAW42 GDSC2 -0.2812 4.3504 -8.1559 1.0003
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DAN-G GDSC2 -9.054 -7.7272 -9.0759 24.2969
QGP-1 GDSC2 -8.8053 12.4059 -18.025 42.8996
MIA PaCa-2 GDSC2 -8.7539 -7.5141 -8.7801 21.3076
PaTu 8902 GDSC2 -8.7385 -7.9833 -8.74 21.0275
Panc 08.13 GDSC2 -8.3485 -5.9133 -8.7447 19.2645
Panc 02.03 GDSC2 -7.8314 -5.6392 -8.3055 14.5746
Panc 10.05 GDSC2 -7.5545 -4.3559 -8.6135 15.3688
PSN1 GDSC2 -7.5268 -4.808 -8.3719 13.8027
Capan-1 GDSC2 -7.4606 -5.5526 -7.9617 11.0679
PaTu 8988t GDSC2 -7.4333 9.6054 -15.4354 37.2094
PL4 GDSC2 -7.2431 -5.2212 -7.9004 9.8883
BxPC-3 GDSC2 -7.2264 -5.8394 -7.5956 7.9653
HuP-T3 GDSC2 -7.2139 -4.347 -8.2961 12.236
KP-4 GDSC2 -7.1007 4.7228 -12.7122 31.2532
CFPAC-1 GDSC2 -6.8612 -2.629 -8.8352 14.3972
AsPC-1 GDSC2 -6.8291 -4.3882 -7.9295 8.6937
HPAC GDSC2 -6.776 -5.3987 -7.3798 5.0584
HPAF-II GDSC2 -6.7523 -4.9465 -7.5845 6.2787
SU.86.86 GDSC2 -6.5484 7.2099 -13.4914 31.5926
Capan-2 GDSC2 -6.5363 2.4612 -11.1071 24.5779
KP-2 GDSC2 -6.3821 -3.5364 -7.9852 7.7572
KP-3 GDSC2 -6.2156 0.1226 -9.6772 17.2178
KP-1N GDSC2 -6.0645 -1.4961 -8.7523 11.6271
YAPC GDSC2 -0.3147 19.8916 -15.0794 23.0792
HuP-T4 GDSC2 -0.0441 8.8956 -9.8471 6.6677
SUIT-2 GDSC2 -0.0388 2.9881 -7.6044 0.1138
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H GDSC2 -8.3035 -5.989 -8.6683 18.6391
NCI-H28 GDSC2 -7.8653 -5.8328 -8.2612 14.4539
MPP 89 GDSC2 -7.7954 -5.8068 -8.198 13.7983
IST-Mes1 GDSC2 -7.6224 -4.9117 -8.4173 14.4317
NCI-H2052 GDSC2 -7.5785 -4.6898 -8.4782 14.6373
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LNCaP clone FGC GDSC2 -8.9823 -6.0766 -9.3706 25.5158
VCaP GDSC2 -7.9794 6.4458 -14.3325 37.0318
22Rv1 GDSC2 -7.4128 1.141 -11.1942 27.6097
DU145 GDSC2 -7.0312 -4.2066 -8.1986 11.0233
PC-3 GDSC2 -6.8031 -2.1742 -9.0128 15.268
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC2 -7.8696 -6.0895 -8.1653 13.9183
Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IGR-1 GDSC2 -10.08 -8.5092 -10.0916 34.5399
G-mel GDSC2 -9.8296 -8.4336 -9.838 32.0117
WM115 GDSC2 -9.5613 -8.3241 -9.5676 29.3084
RPMI-7951 GDSC2 -9.3669 -7.6967 -9.4081 27.535
LOX-IMVI GDSC2 -9.3274 -8.4379 -9.3285 26.9354
HMV-II GDSC2 -9.2249 -7.088 -9.353 26.5603
GAK GDSC2 -9.2086 -8.3206 -9.21 25.7447
IGR-37 GDSC2 -9.0045 -6.1659 -9.3648 25.5871
A101D GDSC2 -8.9852 -6.8016 -9.1577 24.394
Mel JuSo GDSC2 -8.9553 -6.4192 -9.2311 24.6468
SK-MEL-24 GDSC2 -8.7346 -5.4129 -9.3493 24.2937
A2058 GDSC2 -8.7098 -7.6057 -8.726 20.8141
WM278 GDSC2 -8.6603 -6.8288 -8.7969 20.9482
UACC-62 GDSC2 -8.6326 -7.9936 -8.6332 19.9604
SK-MEL-5 GDSC2 -8.6073 -5.5957 -9.1423 22.6079
SH-4 GDSC2 -8.5873 -5.9313 -8.9946 21.7021
CP66-MEL GDSC2 -8.4425 -6.9219 -8.5384 18.5474
SK-MEL-2 GDSC2 -8.4222 -6.5744 -8.604 18.8065
A-375 GDSC2 -8.4094 -6.8788 -8.512 18.2508
G-361 GDSC2 -8.3815 -6.6865 -8.5287 18.211
HT-144 GDSC2 -7.9677 -3.6605 -9.344 21.1402
COLO 679 GDSC2 -7.9555 -4.8085 -8.7977 17.9664
WM793 GDSC2 -7.8592 -5.9253 -8.2177 14.1765
WM1552C GDSC2 -7.8467 -5.6221 -8.3286 14.772
COLO 792 GDSC2 -7.7757 11.2278 -16.5396 39.3294
COLO 829 GDSC2 -7.774 3.0161 -12.4452 32.6093
M14 GDSC2 -7.7461 -4.1813 -8.8819 17.6689
CHL-1 GDSC2 -7.3721 -4.3624 -8.4366 13.646
UACC-257 GDSC2 -7.3611 -5.3046 -7.9763 10.7823
WM35 GDSC2 -7.1167 4.5284 -12.6288 31.0864
WT2-iPS GDSC2 -6.5289 -2.5787 -8.5814 11.8713
⏷ Show the Full List of 31 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC2 -8.9235 -8.006 -8.927 22.8943
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Rh41 GDSC2 -9.023 -7.9402 -9.0309 23.9148
SW982 GDSC2 -8.7632 -7.3374 -8.8109 21.5115
HT-1080 GDSC2 -8.6586 -6.9385 -8.7697 20.7949
KYM-1 GDSC2 -8.5687 -7.6082 -8.5793 19.3696
EW-8 GDSC2 -8.3134 -5.7434 -8.7719 19.2689
RD GDSC2 -7.8187 -5.8461 -8.2066 13.9439
SK-LMS-1 GDSC2 -7.8067 -5.663 -8.2697 14.264
MES-SA GDSC2 -7.7872 -5.8447 -8.1739 13.6238
GCT GDSC2 -7.6746 -6.0187 -7.9849 12.0594
G-401 GDSC2 -7.607 5.8393 -13.7052 34.8918
RKN GDSC2 -7.6028 -4.9469 -8.3816 14.1429
G-402 GDSC2 -7.588 -5.4093 -8.1551 12.7206
Rh30 GDSC2 -7.4008 -6.3007 -7.5837 8.5971
VA-ES-BJ GDSC2 -7.2076 -5.3208 -7.8187 9.2577
SK-UT-1 GDSC2 -7.0834 -4.8283 -7.9397 9.5776
SW684 GDSC2 -7.0211 -4.0758 -8.2544 11.3387
SW872 GDSC2 -6.8858 1.3624 -10.8503 24.62
A-204 GDSC2 -6.1322 1.0326 -10.0645 18.9241
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 21 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NUGC-4 GDSC2 -10.1264 -8.6164 -10.135 34.9906
AGS GDSC2 -9.5157 9.1564 -17.0487 43.9911
NUGC-3 GDSC2 -9.1563 -7.9131 -9.1695 25.2791
SK-GT-2 GDSC2 -8.9989 -6.9671 -9.1335 24.3305
ECC10 GDSC2 -8.9902 -8.2297 -8.991 23.5495
RF-48 GDSC2 -8.9644 -7.1802 -9.0527 23.7412
NCI-N87 GDSC2 -8.9351 -3.2429 -10.4948 30.6687
23132/87 GDSC2 -8.9188 -6.8832 -9.0655 23.5919
KATO III GDSC2 -8.8135 -7.3138 -8.8681 22.0519
OCUM-1 GDSC2 -8.4319 -6.4382 -8.655 19.1301
Hs 746.T GDSC2 -8.4054 -6.6254 -8.5713 18.552
IM95 GDSC2 -8.327 -6.4843 -8.5266 17.9511
RERF-GC-1B GDSC2 -8.2589 -6.1343 -8.5678 17.8786
MKN1 GDSC2 -8.1438 -6.5874 -8.2965 15.8595
SNU-5 GDSC2 -7.974 -6.008 -8.3079 15.1786
HGC-27 GDSC2 -7.554 -5.3954 -8.127 12.4211
GCIY GDSC2 -7.2829 -3.5906 -8.731 15.1327
MKN28 GDSC2 -7.1021 4.204 -12.4542 30.5843
SNU-1 GDSC2 -6.803 -4.1044 -8.0485 9.3629
MKN45 GDSC2 -0.5967 13.0245 -12.0115 15.3713
SNG-M GDSC2 -7.584 -5.9575 -7.9139 11.2729
⏷ Show the Full List of 21 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
K5 GDSC2 -10.2442 -8.7726 -10.2503 36.1601
IHH-4 GDSC2 -9.414 -8.4582 -9.4155 27.8062
8305C GDSC2 -9.0789 -6.9166 -9.2321 25.2295
ASH-3 GDSC2 -8.499 -6.7817 -8.6325 19.3144
FTC-133 GDSC2 -8.469 -6.4859 -8.681 19.4405
CAL-62 GDSC2 -8.4016 -6.0817 -8.7405 19.4711
B-CPAP GDSC2 -8.3378 -6.1417 -8.6505 18.6874
8505C GDSC2 -8.2916 -6.7688 -8.4096 17.1525
WRO GDSC2 -8.0089 -2.046 -10.1602 25.4567
HTC-C3 GDSC2 -7.7215 -5.8169 -8.1163 13.0187
BHT-101 GDSC2 -7.2619 -4.5806 -8.227 11.9724
TT2609-C02 GDSC2 -6.9177 -3.9881 -8.2063 10.709
⏷ Show the Full List of 12 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SCC-9 GDSC2 -9.7971 -7.5676 -9.884 32.0761
HSC-2 GDSC2 -9.3413 -8.0428 -9.3534 27.1301
NCI-H3118 GDSC2 -9.2162 -6.4428 -9.5085 27.329
BB49-HNC GDSC2 -9.176 -5.8313 -9.6651 27.9455
BICR 22 GDSC2 -9.0877 -7.4001 -9.1489 24.837
SAS GDSC2 -9.069 -7.6 -9.1036 24.5124
Ca9-22 GDSC2 -8.8906 -6.859 -9.0406 23.3272
SCC-4 GDSC2 -8.8317 -5.5423 -9.4021 25.0051
HO-1-N-1 GDSC2 -8.7674 -7.7242 -8.7782 21.3645
CAL-27 GDSC2 -8.7031 -7.3373 -8.7468 20.8875
BICR 10 GDSC2 -8.6385 -5.3401 -9.2766 23.4816
HSC-3 GDSC2 -8.6358 -6.847 -8.7658 20.6674
FaDu GDSC2 -8.609 -4.0593 -9.7962 26.088
DOK GDSC2 -8.5879 -6.8149 -8.7213 20.2057
BICR 78 GDSC2 -8.5277 -5.4533 -9.1139 22.1083
SCC-15 GDSC2 -8.3354 -5.7099 -8.8083 19.5692
SAT [Human HNSCC] GDSC2 -8.295 -5.9975 -8.656 18.5327
JHU-022 GDSC2 -8.2661 -5.5779 -8.7873 19.1578
CAL-33 GDSC2 -8.1573 -5.8179 -8.5766 17.4934
Detroit 562 GDSC2 -8.1094 -5.6084 -8.6096 17.4835
SKN-3 GDSC2 -7.82 -3.7848 -9.142 19.4511
LB771-HNC GDSC2 -7.5624 -4.7812 -8.4194 14.2219
PCI-04B GDSC2 -7.4802 -5.6053 -7.958 11.1215
OSC-20 GDSC2 -7.1869 7.8455 -14.3459 34.9215
HSC-4 GDSC2 -7.1005 -5.7871 -7.494 6.8764
UPCI-SCC-090 GDSC2 -0.2848 25.6422 -17.8432 27.9271
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 13 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KU-19-19 GDSC2 -10.0534 -8.4966 -10.0648 34.2718
BFTC-905 GDSC2 -8.6523 -6.7309 -8.8126 20.995
RT-112 GDSC2 -8.2589 -3.2198 -9.8359 24.8583
5637 GDSC2 -7.8308 -5.8426 -8.2207 14.0759
HT-1197 GDSC2 -7.7372 -5.95 -8.0786 12.8632
CAL-29 GDSC2 -7.5327 -5.9262 -7.8731 10.8245
TCCSUP GDSC2 -7.5081 -4.7068 -8.4016 13.9158
647V GDSC2 -7.4852 -2.5397 -9.4333 19.8809
639V GDSC2 -7.1966 -6.3312 -7.3541 6.4153
SW1710 GDSC2 -6.8941 -3.9141 -8.2225 10.7367
SW780 GDSC2 -6.8046 -3.3246 -8.4393 11.8111
RT-4 GDSC2 -1.0406 8.5537 -10.2372 9.4969
J82 GDSC2 0.0426 6.2767 -8.7418 2.4967
⏷ Show the Full List of 13 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PA-1 GDSC2 -10.6265 -9.4718 -10.6271 39.9691
LB831-BLC GDSC2 -9.3149 -5.7756 -9.8348 29.4491
NEC8 GDSC2 -9.1526 -7.94 -9.1642 25.2338
DoTc2 4510 GDSC2 -9.0606 -7.7094 -9.0843 24.3728
PWR-1E GDSC2 -9.0285 -7.5758 -9.0635 24.1082
C-33 A GDSC2 -9.0176 -7.4538 -9.0666 24.0708
HEY GDSC2 -8.8496 -6.7183 -9.0312 23.0852
Ca Ski GDSC2 -8.833 -7.0581 -8.9339 22.4898
CAL-39 GDSC2 -8.6922 -5.997 -9.0842 22.6593
SKN GDSC2 -8.6723 -7.0216 -8.7671 20.8462
OVMIU GDSC2 -8.5769 -6.1202 -8.9166 21.2233
BPH-1 GDSC2 -8.4975 -5.6119 -9.0191 21.4492
MS751 GDSC2 -8.4828 -6.159 -8.8014 20.1677
SKG-IIIa GDSC2 -8.2567 -6.1376 -8.5643 17.8491
SiSo GDSC2 -8.1898 -3.9385 -9.4312 22.4761
HEC-1 GDSC2 -8.0498 -5.5923 -8.5536 16.9138
C-4-I GDSC2 -7.6949 -4.3382 -8.7578 16.7451
DSH1 GDSC2 -7.6907 -5.5018 -8.2189 13.5012
ME-180 GDSC2 -7.6676 -4.0908 -8.8491 17.1876
HeLa GDSC2 -7.4384 -1.8234 -9.7445 21.3714
TC-YIK GDSC2 -7.0278 -4.9961 -7.8061 8.5565
HT-3 GDSC2 -6.8733 -3.531 -8.3954 11.75
SiHa GDSC2 -6.8723 2.9486 -11.6318 27.4399
SW756 GDSC2 -6.5533 2.9155 -11.3482 25.521
OVCA420 GDSC2 -6.5278 -4.1558 -7.7926 6.942
PEO1 GDSC2 -6.3601 -1.5047 -8.981 13.7793
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Romidepsin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sarecycline DMLZNIQ Moderate Decreased clearance of Romidepsin due to the transporter inhibition by Sarecycline . Acne vulgaris [ED80] [20]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Romidepsin and Ivosidenib. Acute myeloid leukaemia [2A60] [21]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Romidepsin and Midostaurin. Acute myeloid leukaemia [2A60] [22]
Arn-509 DMT81LZ Moderate Increased metabolism of Romidepsin caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [20]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Romidepsin and Gilteritinib. Acute myeloid leukaemia [2A60] [23]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Romidepsin and Oliceridine. Acute pain [MG31] [24]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Romidepsin and Ivabradine. Angina pectoris [BA40] [25]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Romidepsin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [26]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Romidepsin and Levalbuterol. Asthma [CA23] [27]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Romidepsin caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [20]
Erdafitinib DMI782S Moderate Decreased clearance of Romidepsin due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [28]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Romidepsin caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [29]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Romidepsin and Eribulin. Breast cancer [2C60-2C6Y] [22]
Tucatinib DMBESUA Moderate Decreased metabolism of Romidepsin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [20]
Alpelisib DMEXMYK Moderate Decreased clearance of Romidepsin due to the transporter inhibition by Alpelisib. Breast cancer [2C60-2C6Y] [20]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Romidepsin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [30]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Romidepsin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [31]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Romidepsin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [27]
Regorafenib DMHSY1I Moderate Decreased clearance of Romidepsin due to the transporter inhibition by Regorafenib. Colorectal cancer [2B91] [20]
Ulipristal DMBNI20 Moderate Decreased clearance of Romidepsin due to the transporter inhibition by Ulipristal. Contraceptive management [QA21] [20]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Romidepsin and Pasireotide. Cushing syndrome [5A70] [22]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Romidepsin and Osilodrostat. Cushing syndrome [5A70] [21]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Romidepsin caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [32]
Ivacaftor DMZC1HS Moderate Decreased clearance of Romidepsin due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [20]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Romidepsin and Deutetrabenazine. Dystonic disorder [8A02] [33]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Romidepsin and Ingrezza. Dystonic disorder [8A02] [34]
Stiripentol DMMSDOY Moderate Decreased metabolism of Romidepsin caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [35]
Boceprevir DMBSHMF Moderate Decreased metabolism of Romidepsin caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [20]
Daclatasvir DMSFK9V Moderate Decreased clearance of Romidepsin due to the transporter inhibition by Daclatasvir. Hepatitis virus infection [1E50-1E51] [20]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Romidepsin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [36]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Romidepsin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [20]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Romidepsin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [22]
Teriflunomide DMQ2FKJ Major Additive myelosuppressive effects by the combination of Romidepsin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [37]
BMS-201038 DMQTAGO Moderate Decreased clearance of Romidepsin due to the transporter inhibition by BMS-201038. Hyper-lipoproteinaemia [5C80] [20]
Tolvaptan DMIWFRL Moderate Decreased clearance of Romidepsin due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [20]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Romidepsin and Polyethylene glycol. Irritable bowel syndrome [DD91] [25]
Denosumab DMNI0KO Moderate Additive myelosuppressive effects by the combination of Romidepsin and Denosumab. Low bone mass disorder [FB83] [38]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Romidepsin and Crizotinib. Lung cancer [2C25] [39]
Brigatinib DM7W94S Moderate Increased metabolism of Romidepsin caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [40]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Romidepsin and Ceritinib. Lung cancer [2C25] [22]
PF-06463922 DMKM7EW Moderate Increased metabolism of Romidepsin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [41]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Romidepsin and Osimertinib. Lung cancer [2C25] [42]
Capmatinib DMYCXKL Moderate Decreased clearance of Romidepsin due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [20]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Romidepsin and Selpercatinib. Lung cancer [2C25] [43]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Romidepsin and Lumefantrine. Malaria [1F40-1F45] [44]
IPI-145 DMWA24P Moderate Decreased metabolism of Romidepsin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [45]
Ponatinib DMYGJQO Moderate Decreased clearance of Romidepsin due to the transporter inhibition by Ponatinib. Mature B-cell lymphoma [2A85] [20]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Romidepsin and Vemurafenib. Melanoma [2C30] [22]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Romidepsin and LGX818. Melanoma [2C30] [46]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Romidepsin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [25]
Lasmiditan DMXLVDT Moderate Decreased clearance of Romidepsin due to the transporter inhibition by Lasmiditan. Migraine [8A80] [47]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Romidepsin and Panobinostat. Multiple myeloma [2A83] [48]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Romidepsin and Tecfidera. Multiple sclerosis [8A40] [49]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Romidepsin and Siponimod. Multiple sclerosis [8A40] [44]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Romidepsin and Fingolimod. Multiple sclerosis [8A40] [50]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Romidepsin and Ocrelizumab. Multiple sclerosis [8A40] [51]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Romidepsin and Ozanimod. Multiple sclerosis [8A40] [25]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Romidepsin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [25]
Rolapitant DM8XP26 Moderate Decreased clearance of Romidepsin due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [20]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Romidepsin and Entrectinib. Non-small cell lung cancer [2C25] [25]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Romidepsin and Rucaparib. Ovarian cancer [2C73] [22]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Romidepsin and Triclabendazole. Parasitic worm infestation [1F90] [24]
Istradefylline DM20VSK Moderate Decreased clearance of Romidepsin due to the transporter inhibition by Istradefylline. Parkinsonism [8A00] [20]
Abametapir DM2RX0I Moderate Decreased metabolism of Romidepsin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [52]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Romidepsin and Macimorelin. Pituitary gland disorder [5A60-5A61] [53]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Romidepsin and Lefamulin. Pneumonia [CA40] [21]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Romidepsin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [20]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Romidepsin and Degarelix. Prostate cancer [2C82] [25]
Enzalutamide DMGL19D Moderate Increased metabolism of Romidepsin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [20]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Romidepsin and Relugolix. Prostate cancer [2C82] [25]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Romidepsin and Rilonacept. Rheumatoid arthritis [FA20] [54]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Romidepsin and Golimumab. Rheumatoid arthritis [FA20] [55]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Romidepsin and Amisulpride. Schizophrenia [6A20] [56]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Romidepsin and Asenapine. Schizophrenia [6A20] [22]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Romidepsin when combined with Anthrax vaccine. Sepsis [1G40-1G41] [57]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Romidepsin caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [25]
Larotrectinib DM26CQR Moderate Decreased metabolism of Romidepsin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [44]
LEE011 DMMX75K Major Decreased metabolism of Romidepsin caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [22]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Romidepsin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [25]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Romidepsin and Pitolisant. Somnolence [MG42] [22]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Romidepsin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [22]
Fostamatinib DM6AUHV Moderate Decreased clearance of Romidepsin due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [58]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Romidepsin and Lenvatinib. Thyroid cancer [2D10] [22]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Romidepsin and Cabozantinib. Thyroid cancer [2D10] [25]
⏷ Show the Full List of 84 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
DL-alpha-tocopherol E00052 2116 Antioxidant
Ethanol E00023 702 Antimicrobial preservative; Penetration agent; Solvent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Romidepsin 10mg/2ml solution 10mg/2ml Solution Intravenous
Romidepsin 27.5mg/5.5ml solution 27.5mg/5.5ml Solution Intravenous
Romidepsin 10mg/vial powder 10mg/vial Powder Intravenous
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7006).
2 Romidepsin FDA Label
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 BDDCS applied to over 900 drugs
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
8 Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503.
9 A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol. 2011 May;13(5):509-16.
10 Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503.
11 FDA Label of Romidepsin. The 2020 official website of the U.S. Food and Drug Administration.
12 Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J Pharmacol Exp Ther. 2005 Jul;314(1):467-75. doi: 10.1124/jpet.105.083956. Epub 2005 Apr 15.
13 Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras. Oncotarget. 2016 Oct 25;7(43):69804-69815. doi: 10.18632/oncotarget.12001.
14 5-Aza-2'-deoxycytidine and depsipeptide synergistically induce expression of BIK (BCL2-interacting killer). Biochem Biophys Res Commun. 2006 Dec 15;351(2):455-61. doi: 10.1016/j.bbrc.2006.10.055. Epub 2006 Oct 18.
15 Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino- methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int J Cancer. 2004 Jun 10;110(2):301-8. doi: 10.1002/ijc.20117.
16 Aberrant promoter methylation of the ABCG2 gene in renal carcinoma. Mol Cell Biol. 2006 Nov;26(22):8572-85.
17 Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res. 2004 Mar 1;10(5):1813-25. doi: 10.1158/1078-0432.ccr-0901-3.
18 Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clin Cancer Res. 2008 Jan 15;14(2):549-58. doi: 10.1158/1078-0432.CCR-07-1934.
19 Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood. 2006 Feb 15;107(4):1546-54. doi: 10.1182/blood-2004-10-4126. Epub 2005 Oct 13.
20 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
21 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
22 Canadian Pharmacists Association.
23 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
24 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
25 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
26 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
27 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
28 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
29 Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
30 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
31 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
32 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
33 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
34 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
35 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
36 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
37 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
38 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
39 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
40 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
41 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
42 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
43 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
44 Cerner Multum, Inc. "Australian Product Information.".
45 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
46 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
47 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
48 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
49 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
50 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
51 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
52 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
53 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
54 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
55 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
56 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
57 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
58 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.